Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Monthly Archives: September 2014

Lt. Gov. Guadagno to Keynote at Statewide Hispanic Chamber of Commerce’s Convention October 23

Newark, NJ, September 29, 2014 ― The Statewide Hispanic Chamber of Commerce of New Jersey (SHCC-NJ) has announced that Lieutenant Governor Kim Guadagno will serve as the keynote speaker at its 24th Annual Convention & Awards Luncheon that will take place on October 23 at The Brownstone in Paterson, NJ.

The Honorable Joey Torres, Mayor of Paterson, will give welcoming remarks.

This annual event will help attendees taking advantage of the many exciting opportunities to learn the tools and skills that business owners, entrepreneurs, and individuals need to be successful, especially in these economic times.   Continue reading

R&D Council of NJ Names 2014 Edison Patent and Special Recognition Honorees; Event Set for Nov. 6

Chatham, NJ, September 25, 2014 ― The Research & Development Council of New Jersey will present its 2014 Edison Patent Awards on November 6 at the Liberty Science Center in Jersey City, NJ.

This year’s Edison Patent Award winners are:

  • Immunomedics (Biotechnology)
  • TE Connectivity SubCom (Communication Technology)
  • Colgate-Palmolive (Consumer Products)
  • U.S. Army ARDEC (Defense)
  • NJIT (Enabling Technology)
  • Siemens Corporation, Corporate Technology (Energy)
  • BASF (Environmental)
  • Exxon Mobil Research & Engineering Company (Industrial Process)
  • Avaya Labs (Information Technology)
  • Honeywell (Materials Technology)
  • Merck & Co. (Pharmaceutical Process)
  • Novartis Pharmaceuticals Corporation (Pharmaceutical Formulation)
  • Alcatel-Lucent Bell Labs (Telecommunications)

Continue reading

BioNJ Study Looks Beyond Biotech Sector, Finding Contributions, Needs of NJ’s Life Sciences Industry

Trenton, NJ, September 23, 2014 ― Recognizing the continuing evolution of New Jersey’s life sciences industry, BioNJ yesterday released a comprehensive report that documents the ongoing growth of the biotechnology sector in the State and combines and assesses the contributions of the entirety of the life sciences sector to New Jersey’s economy, including employment and economic impact.

BioNJ conducted the study in partnership with EY (formerly known as Ernst & Young) the Edward J. Bloustein School of Planning and Public Policy (Bloustein School) and the New Jersey Department of Labor and Workforce Development’s (LWD) Office of Research and Information.

To access BioNJ’s 35-page report, click here. Continue reading

Rutgers Receives $2M NIH Grant to Prepare Biomedical Students for Industry Roles

New Brunswick, NJ, September 22, 2014 ― Rob Forman and Carl Blesch report today that Rutgers is one of seven institutions in the country selected by the National Institutes of Health (NIH) to receive this year’s BEST Award — a $2 million grant designed to expose many of the university’s most promising biomedical sciences graduate trainees to career opportunities that go beyond the academic path that they have traditionally taken.

The award funds development of the Rutgers Interdisciplinary Job Opportunities for Biomedical Scientists (iJOBs) program.

It includes courses, seminars, shadowing, mentoring and networking activities to better prepare doctoral students and postdoctoral scientists for a broad spectrum of careers within the biomedical science and engineering ecosystem, including those with established companies, government agencies, entrepreneurial ventures and nonprofit institutions.

Traditionally, graduate training in biomedical sciences and engineering at universities throughout the country has focused on preparing students for academic research careers. But, according to the NIH, fewer than half of doctoral candidates in the biomedical sciences now end up in academia — largely because the economics of universities are changing — so NIH instituted the program last year to address that issue and better prepare these students for non-academic careers.

The university’s successful application to participate in BEST, which stands for Broadening Experiences in Scientific Training, was submitted jointly by two major Rutgers entities:  the Center for Innovative Ventures of Emerging Technologies (CIVET) and the Graduate School of Biomedical Sciences (GSBS), a school located in both New Brunswick and Newark that became part of the university in July 2013 as part of Rutgers’ integration with most units of the former University of Medicine and Dentistry of New Jersey (UMDNJ).

“This is a true triumph enabled by the Rutgers-UMDNJ merger,” says Martin Yarmush, the director of CIVET.  “Combining top engineering students and pre-and postdoctoral biomedical scientists within one powerhouse institution was a great incentive for NIH to choose us over more than 100 other universities that also competed for the award.”

CIVET has been guiding Rutgers researchers, both students and faculty, in translation of their work to practical application and successful commercialization. In support of that goal, the center offers courses, seminars, and personal coaching — provided by a star-studded adjunct faculty of more than 60 experts in various technical, business and legal disciplines — on how to communicate commercial value and tap entrepreneurial resources such as venture capital.

It also has successfully competed for multi-year NIH and NCIIA grants to organize and implement clinical immersion programs where biomedical engineers work with health sciences clinical and research faculty to bring innovations from the laboratory into medical practice.

“We have been doing the kind of work that the National Institutes of Health is looking to establish on a broad scale,” said Susan Engelhardt, Executive Director of CIVET.  “As we implement the iJOBS Program, we will ask partnering industrial and business professionals to define the skills they want in their doctorally trained professionals, and will involve them in the workshops and mentoring programs we create to train these future employees.”

The programs that Rutgers develops will also be available to alumni of doctoral programs within the first five years of their professional careers.  These programs will be organized into five particular areas of focus:

  • Science and health policy: laws and regulations that affect research and society’s health care goals
  • Industrial development and business management: management skills for the biomedical corporate environment
  • Intellectual property management: patent protection and intellectual property licensing for research results
  • Clinical and regulatory testing and support: interactions with regulatory agencies and compliance with safety standards
  • Health and science data analysis: developing software for research data analysis and validation.

The preparation for potential careers in business is especially revolutionary in the biomedical sciences.

Kathleen Scotto, the dean of GSBS, recalls training for her doctorate in the 1980s.  “If someone like me had told the person running the lab about wanting to work somewhere other than academia, we would have been told to leave the lab.  Careers in industry are now very attractive to people in my field, and industry leaders such as BioNJ and the Healthcare Institute of New Jersey helped Rutgers secure this grant and will be involved throughout in helping to instruct our advanced students.”

Shirley Tilghman, then president of Princeton University, co-chaired the NIH panel that recommended in 2012 that graduate education in the biomedical sciences be broadened to include greater exposure to non-academic opportunities.

Tilghman, a leading figure in the field of molecular biology, says she is “delighted” that Rutgers is an award recipient.  “With its commitment to diversifying the career options of this generation of biomedical science and engineering graduate students and postdoctoral fellows,” says Tilghman, “Rutgers will serve both the students’ interests and the interests of the country. It will serve as a model for other institutions throughout the country to emulate.”

The Principal Investigators of the grant are Martin L. Yarmush, director of CIVET and the Paul and Mary Monroe Chair and Distinguished Professor of Biomedical Engineering; and James H. Millonig, senior associate dean, Rutgers Graduate School of Biomedical Sciences and associate professor of neuroscience and cell biology at Rutgers Robert Wood Johnson Medical School (RWJMS).

Other key personnel leading the implementation include:

  • Susan Engelhardt, executive director of CIVET;
  • Stephen Garrett, assistant dean of curriculum, GSBS, and associate professor of microbiology and molecular genetics at Rutgers New Jersey Medical School;
  • Janet Alder, director of graduate academic and student affairs, GSBS, and associate professor of neuroscience and cell biology at RWJMS;
  • François Berthiaume, research coordinator of CIVET and associate professor of biomedical engineering

 

National Journal: NJ Working to Build a Diverse New Generation of Science, Tech Innovators

Washington, DC,  September 19, 2014 ― Writing in National Journal, Anthony Cicatiello, president of the Research & Development Council of New Jersey, and David Hodges, director of the Governor’s STEM Scholars, write that New Jersey — the state that gave the world the light bulb, the silicon transistor, and the antibiotic streptomycin — is working now to lead the way again.

“In New Jersey,” Cicatiello and Hodges write, “the clustering of highly educated people, top companies, and world-renowned research universities has made it one of the premier places in the country for biopharmaceuticals, medical devices, chemical production, and knowledge creation.”

“People like Albert Einstein and Thomas Edison, institutions like Rutgers and Johnson & Johnson, and inventions like the transistor and phonograph all helped the state become a hub for innovation.” Continue reading

New Jersey EMS Task Force Celebrates 10th Anniversary with Exhibition

Trenton, NJ, September 19, 2014 ― The New Jersey EMS Task Force, a statewide organization created in the aftermath of the 9/11 terrorist attacks, will mark its 10th anniversary with a major exhibit of statewide equipment and response capabilities on Saturday, Sept. 20, 2014, from 8 a.m. to 3 p.m. at the NJ Convention & Exhibition Center, Raritan Center, Edison, NJ.

The EMS Task Force is a team of more than 200 EMS personnel statewide trained to respond to natural and man-made disasters.  Over the last decade, it has responded to Super Storm Sandy, Hurricane Irene and the crash of US Airways Flight 1549. Continue reading

New Rutgers Graduate Program Trains Students to Meet Changing Health Care Demands

New Brunswick, NJ, September 15, 2014 ― Rutgers, The State University of New Jersey is now offering a Master of Science Degree in Health Outcomes, Policy and Economics.

The new joint-degree program — conceived by Christopher Molloy, Rutgers senior vice president of research and economic development and the former dean of the Ernest Mario School of Pharmacy at Rutgers — brings together the Rutgers schools of Pharmacy and Public Health. Continue reading

Rutgers Receives $10 Million Donation for Cancer Research

New Brunswick, NJ, September 9, 2014 ― The Star-Ledger today reports that Rutgers, The State University of New Jersey has received a $10 million anonymous grant to help its scientists discover targeted therapies for hard-to-treat cancers.

The donation, given over two years, will fund everything from clinical trials to undergraduate training in the growing field known as “precision medicine.”

The gift includes support for the advanced genomic analysis of cancers undertaken at RUCDR Infinite Biologics, the repository of cell and DNA tissue samples that is now part of the Rutgers Human Genetics Institute of New Jersey. Continue reading

FDA Drug Approval for 2014 Is Ahead of 2013

New York, NY, September 8, 2014 WSJ Pharmalot, a pharmaceutical industry blog of The Wall Street Journal, reports an encouraging statistic:  For the year to date, the Food and Drug Administration (FDA) has approved more drugs than it did in all of 2013.

According to Pharmalot, so far this year, the FDA has approved 27 novel new medicines, a tally that includes biologics and which matches the 27 such medicines approved for all of 2013.  At this rate, the FDA may come close to matching the 39 novel new medicines approved in 2012. Continue reading

Rutgers Cancer Institute of NJ to Host ‘Oncology Pipeline Update’ Seminar September 30

New Brunswick, NJ, September 8, 2014 Rutgers Cancer Institute of New Jersey (CINJ) will host “Oncology Pipeline Update” on Tuesday, September 30 from 4:00 to 6:00 p.m. in CINJ’s Auditorium A and B, 195 Little Albany Street, New Brunswick.   The HealthCare Institute of New Jersey (HINJ) is an event co-sponsor.

This is the inaugural seminar in the Rutgers University – Industry Cancer Seminar Series, which is designed to foster collaboration and networking between Rutgers faculty and strategic industry partners.

The September 30 seminar will provide an update on drugs in the developmental pipeline at Bristol-Myers Squibb and current basic and clinical research projects at Rutgers, with the objective of initiating a dialogue for validating novel cancer therapeutics. Continue reading